Inclusion body myositis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Sun, 31 May 2026 04:01:59 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Inclusion body myositis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Title: Long-term safety and effectiveness study of Ulviprubart in patients with inclusion body myositis who completed previous treatment https://clinicaltrials.eu/trial/study-on-long-term-safety-of-ulviprubart-for-patients-with-inclusion-body-myositis/ Wed, 29 Apr 2026 15:04:25 +0000 https://clinicaltrials.eu/trial/study-on-long-term-safety-of-ulviprubart-for-patients-with-inclusion-body-myositis/ This study focuses on evaluating a treatment for people with inclusion body myositis, a rare muscle disorder that causes progressive muscle weakness and wasting. The medication being tested is called ulviprubart (also known as ABC008), which is given as a subcutaneous injection under the skin. This is a long-term study to understand how safe and effective the treatment is over an extended period.

The study is designed for patients who have already completed previous trials of ulviprubart. During the study, participants will receive regular injections of the medication and will be monitored for any side effects. The treatment period may last up to 152 weeks, with participants receiving doses up to 2.0 milligrams per kilogram of body weight.

The main goal is to evaluate the long-term safety and how well patients tolerate ulviprubart. The study will track any changes in muscle strength and function throughout the treatment period. The medication being tested is a specialized type of antibody that has been designed to target specific proteins involved in the disease process of inclusion body myositis.

]]> Study on Ruxolitinib for Treating Inclusion Body Myositis in Patients https://clinicaltrials.eu/trial/study-on-ruxolitinib-for-treating-inclusion-body-myositis-in-patients/ Wed, 29 Apr 2026 14:58:34 +0000 https://clinicaltrials.eu/trial/study-on-ruxolitinib-for-treating-inclusion-body-myositis-in-patients/ This clinical trial is focused on studying the effects of a medication called ruxolitinib, also known by its code name INCB018424, in treating a condition called Inclusion Body Myositis (IBM). IBM is a rare muscle disease that causes muscle weakness and inflammation. The purpose of the study is to see if ruxolitinib can improve the ability of patients with IBM to move around after one year of treatment.

Participants in the study will receive either ruxolitinib or a placebo, which looks like the medication but does not contain the active ingredient. The study will last for one year, during which participants will take the medication in the form of tablets. The main goal is to see if there is an improvement in the distance patients can walk in six minutes after the treatment period. Additionally, the study will monitor the safety and tolerance of ruxolitinib in patients with IBM, as well as any changes in muscle strength and overall muscle health.

Throughout the study, various assessments will be conducted to evaluate the effects of the treatment on the quality of life and muscle function of the participants. These assessments will include measurements of muscle strength, walking distance, and other indicators of muscle health. The study aims to provide valuable information on whether ruxolitinib can be an effective treatment option for people living with Inclusion Body Myositis.

]]> Study on the Safety and Effectiveness of ABC008 for Patients with Inclusion Body Myositis https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-abc008-for-patients-with-inclusion-body-myositis/ Wed, 29 Apr 2026 14:26:18 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-abc008-for-patients-with-inclusion-body-myositis/ This clinical trial is focused on studying a disease called Inclusion Body Myositis (IBM), which is a condition that causes muscle weakness and wasting. The study is testing a new treatment called ABC008, which is a type of medication known as a monoclonal antibody. Monoclonal antibodies are proteins designed to target specific parts of the immune system. In this case, ABC008 is designed to bind to a specific receptor on certain immune cells, potentially helping to manage the symptoms of IBM.

The purpose of the study is to determine how effective and safe ABC008 is for people with IBM. Participants in the study will receive either the ABC008 treatment or a placebo, which is a substance with no active medication. The study will last for a period of 76 weeks, during which participants will receive the treatment through injections under the skin. Throughout the study, researchers will monitor the participants’ muscle function and overall health to assess the impact of the treatment.

In addition to evaluating the effectiveness of ABC008, the study will also look at the safety and tolerability of the treatment. This means that researchers will carefully observe any side effects or reactions participants may experience. The study aims to provide valuable information about the potential benefits and risks of using ABC008 for treating Inclusion Body Myositis, which could lead to new treatment options for those affected by this condition.

]]>